JP2017528468A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528468A5
JP2017528468A5 JP2017513506A JP2017513506A JP2017528468A5 JP 2017528468 A5 JP2017528468 A5 JP 2017528468A5 JP 2017513506 A JP2017513506 A JP 2017513506A JP 2017513506 A JP2017513506 A JP 2017513506A JP 2017528468 A5 JP2017528468 A5 JP 2017528468A5
Authority
JP
Japan
Prior art keywords
trastuzumab
population
antibody
relative frequency
galactose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017513506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528468A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/070285 external-priority patent/WO2016037947A1/en
Publication of JP2017528468A publication Critical patent/JP2017528468A/ja
Publication of JP2017528468A5 publication Critical patent/JP2017528468A5/ja
Withdrawn legal-status Critical Current

Links

JP2017513506A 2014-09-10 2015-09-04 ガラクトース操作型免疫グロブリン１抗体 Withdrawn JP2017528468A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14184201.3 2014-09-10
EP14184201 2014-09-10
US201462095912P 2014-12-23 2014-12-23
US62/095,912 2014-12-23
PCT/EP2015/070285 WO2016037947A1 (en) 2014-09-10 2015-09-04 Galactoengineered immunoglobulin 1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020156251A Division JP2021006540A (ja) 2014-09-10 2020-09-17 ガラクトース操作型免疫グロブリン１抗体

Publications (2)

Publication Number Publication Date
JP2017528468A JP2017528468A (ja) 2017-09-28
JP2017528468A5 true JP2017528468A5 (https=) 2018-09-27

Family

ID=51518624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513506A Withdrawn JP2017528468A (ja) 2014-09-10 2015-09-04 ガラクトース操作型免疫グロブリン１抗体

Country Status (5)

Country Link
US (2) US20170253661A1 (https=)
EP (2) EP3191527B1 (https=)
JP (1) JP2017528468A (https=)
CN (2) CN106687481B (https=)
WO (1) WO2016037947A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3559250A1 (en) * 2016-12-21 2019-10-30 H. Hoffnabb-La Roche Ag Re-use of enzymes in in vitro glycoengineering of antibodies
WO2018114877A1 (en) * 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag In vitro glycoengineering of antibodies
MX2019006123A (es) 2016-12-21 2019-08-12 Hoffmann La Roche Metodo para glicomanipulacion in vitro de anticuerpos.
MX2021002792A (es) * 2018-09-11 2021-05-12 Amgen Inc Metodos para modular la citotoxicidad mediada por celulas dependiente de anticuerpos.
WO2021072244A1 (en) * 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
EP4204005A1 (en) * 2020-08-31 2023-07-05 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for coronavirus protein and uses thereof
EP4119672A1 (en) * 2021-07-14 2023-01-18 Sartorius Stedim Cellca GmbH Method of modulating the extent of galactosylation of proteins in mammalian producer cells
CN114167060B (zh) * 2021-11-25 2022-08-05 辽宁师范大学 一种肝癌生物标志物及检测肝癌的试剂盒
EP4441091A4 (en) * 2021-11-30 2025-12-17 Sab Llc UNGULATE-DERIVED POLYCLONAL IMMUNE GLOBULIN SPECIFIC FOR INFLUENCE VAVIRUS AND USES THEREOF

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1308456E (pt) 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
FR2861080B1 (fr) * 2003-10-20 2006-02-17 Lab Francais Du Fractionnement Anticorps presentant un taux de fucose et de galactose optimise
ES2672640T3 (es) * 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
DK1896071T3 (en) * 2005-06-30 2015-05-26 Janssen Biotech Inc Methods and compositions with increased therapeutic activity
CN101646775B (zh) * 2006-12-28 2016-08-24 森托科尔奥索生物科技公司 用于产生脱唾液酸化免疫球蛋白的方法和载体
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
CA2799595C (en) * 2010-05-27 2022-08-16 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
WO2012020065A1 (en) * 2010-08-10 2012-02-16 Glycotope Gmbh Fab-glycosylated antibodies
WO2013021279A2 (en) * 2011-08-10 2013-02-14 Lfb Biotechnologies Highly galactosylated antibodies
JP5854535B2 (ja) * 2011-10-05 2016-02-09 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗体ｇ１グリコフォーム産生のための方法
EP2956485A2 (en) * 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-her2 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2017528468A5 (https=)
WO2013082519A3 (en) Nucleotide-specific recognition sequences for designer tal effectors
US9689016B2 (en) Method for in vivo production of deglycosylated recombinant proteins used as substrate for downstream protein glycoremodeling
CA2922888C (en) Cells producing fc containing molecules having altered glycosylation patterns and methods and use thereof
JP2014525395A5 (https=)
JP2016508515A5 (https=)
WO2014118360A3 (en) Carbohydrate degrading polypeptide and uses thereof
JP2016104045A5 (https=)
WO2014202616A3 (en) Rasamsonia gene and use thereof
WO2017011773A3 (en) Codon-optimized nucleic acids encoding antibodies
WO2013013013A3 (en) Compositions and methods for producing modified glycoproteins
WO2016075662A3 (en) Dna-binding domain of crispr system, non-fucosylated and partially fucosylated proteins, and methods thereof
WO2010132659A3 (en) Anti-human cd52 immunoglobulins
WO2011123830A3 (en) Alpha 1-antitrypsin compositions and methods of making and using same
WO2004074497A3 (en) Endomannosidases in the modification of glycoproteins in eukaryotes
JP2015154787A5 (https=)
EA201071108A1 (ru) Способ и система обеспечения контроля за изготовлением изделий
HK1248714A1 (zh) Ras蛋白的突变的片段
WO2012142434A3 (en) Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
WO2015199387A3 (ko) 가용성 단백질 발현량 및 활성이 증대된 헬리코박터 파일로리 유래 α-1,3 푸코실 전달효소의 유전자와 단백질 및 α-1,3 푸코실올리고당 생산에의 응용
WO2021123184A3 (en) Alpha-amylase variants
MX2013002657A (es) Proceso para la produccion de fibrinogeno.
NZ742745A (en) Variants of chymosin with improved milk-clotting properties
JP2017505620A5 (https=)
JP2020501577A5 (https=)